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Abstract
Recent research findings have provided convincing evidence indicating a role for Interleukin-33 (IL-33) signalling pathway
in a number of central nervous system (CNS) diseases including multiple sclerosis (MS) and Alzheimer’s disease. However,
the exact function of IL-33 molecule within the CNS under normal and pathological conditions is currently unknown.
In this study, we have mapped cellular expression of IL-33 and its receptor ST2 by immunohistochemistry in the brain
tissues of MS patients and appropriate controls; and investigated the functional significance of these findings in vitro
using a myelinating culture system. Our results demonstrate that IL-33 is expressed by neurons, astrocytes and
microglia as well as oligodendrocytes, while ST2 is expressed in the lesions by oligodendrocytes and within and
around axons. Furthermore, the expression levels and patterns of IL-33 and ST2 in the lesions of acute and chronic MS
patient brain samples are enhanced compared with the healthy brain tissues. Finally, our data using rat myelinating
co-cultures suggest that IL-33 may play an important role in MS development by inhibiting CNS myelination.
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Introduction
Signal transduction by Interleukin-33 (IL-33) is implicated
in the pathogenesis of an increasing number of human
diseases [1–3], in which it is generally regarded to act as
an alarmin that alerts the immune system to necrotic cell
injury and tissue damage [4–6]. This response involves a
classical extracellular cytokine signalling pathway involv-
ing the heterodimer receptor complex ST2 and IL-1 recep-
tor accessory protein (IL-1RAcP) [7], or acting as an
intracellular nuclear factor that reduces pro-inflammatory
signalling by sequestering NF-kB [8]. However, a more re-
cent study by Kakkar et al. [9] reported that membrane
bound vesicles containing IL-33 can be secreted by living
cells, indicating a function beyond that of an endogenous
danger signal. Although IL-33 is clearly an important
immunomodulatory cytokine, there are intriguing hints to
suggest that it may also play other roles, in particular in
the central nervous system (CNS) where its expression is
significantly high compared to other tissues [10].
This concept is supported by the important function
of IL-33 in CNS development [11] and its association
with a variety of neurological diseases [3, 12], including
Alzheimer’s disease (AD) in which genetic variants of Il-
33 are associated with increased disease susceptibility
[13, 14]. Amyotrophic lateral sclerosis is also shown to
be associated with reduced serum IL-33 levels compared
with healthy controls [15] which may reflect a corre-
sponding increase in availability of soluble ST2 receptor.
The role of IL-33 in inflammatory CNS diseases such as
multiple sclerosis (MS) is of particular interest as MS is
a disease characterised by immune-mediated demyelin-
ation of axons, thus IL-33 has the potential to modulate
both the immune and the CNS system and therefore to
influence disease pathology. This is supported by recent
findings of increased expression of IL-33 in the
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periphery and CNS tissues of MS patients [16, 17]. How-
ever the pathophysiological significance of these obser-
vations remains obscure, studies on experimental
autoimmune encephalomyelitis (EAE) provide contra-
dictory findings as to the role of IL-33 in neuroinflamma-
tory disease. Ablation of IL-33 signalling by deleting its
receptor in mice resulted in exacerbation of EAE [18, 19],
whilst utilising an IL-33 blocking antibody resulted in the
converse effect, inhibiting disease onset and reducing its
severity [20]. The reason for this dichotomy remains
unknown but may reflect an unexpected role for IL-33
within the CNS compartment, above and beyond its
ability to act as an immunomodulatory cytokine.
Surprisingly despite increased evidence supporting a role
for IL-33 in a variety of CNS diseases, its function within
the CNS under normal and pathological conditions is
unknown. As a first step towards resolving these questions
we determined cellular expression of IL-33 and ST2 by
immunohistochemistry in the brain tissues of MS patients
together with appropriate controls. Following that we in-
vestigated the function of IL-33/ST2 signaling pathway in
CNS using rat CNS myelinating co-cultures.
Materials and Methods
Antibodies
The following primary antibodies were used for human
brain tissues: anti-IL-33 (Enzo Lifescience), anti-ST2
(Sigma-Aldrich), anti-GFAP (DAKO), and anti-Iba1
(Wako). Antibodies against SMI-31 and CA-II were pur-
chased from Abcam. Primary antibodies for immunolabel-
ling cells within the myelinating cultures include: anti-ST2
(Sigma-Aldrich), anti-GFAP (DAKO), anti-SMI-31 (Abcam),
anti-MBP (Chemicon). The antibody O4 [21], and other
anti-NeuN and anti-Olig2 antibodies were purchased
from Millipore. All the primary antibodies were tested and
an optimal dilution of 1:100 of the original purchased
stock was used in staining except CA-II was diluted 1:500.
Appropriate isotype control antibodies, biotinylated anti-
bodies and fluroscence conjugated antibodies were pur-
chased from Sigma-Aldrich, DAKO, R&D Systems or
Jackson Immunoresearch.
MS patient specimens
Archived formalin-fixed, paraffin-embedded brain mate-
rials from 14 MS patients and 6 controls without neuro-
logical disease or evidence of brain lesions were used in
this study. Samples from MS patients have been exten-
sively characterised in the Center for Brain Research of
the Medical University of Vienna. The samples include: 7
acute MS patients (Marburg’s type) with 2 females and an
average age of 49.4 years, these cases all died within one
year after disease onset and were selected because of the
abundance of active MS lesions; 7 chronic MS patients
with 4 females and an average age of 63.1 years, all with
a clinical course of secondary progressive MS, these
cases were selected on the presence of large numbers of
slowly expanding and inactive chronic lesions; 6 healthy
controls with 4 female and an average age of 58.7 years.
Immunohistochemical staining was performed on the
brain samples of all the patients and controls. Images
between samples in each group were compared and
verified by MS pathologists, representative images of con-
sistent data in each group were presented. The study was
approved by the ethics committee of the Medical Univer-
sity of Vienna (EK Nr: 078/11/2015).
Immunohistochemical staining
Paraffin slides were heated in an oven at 60 °C for 35 min
to soften the wax. The slides were then deparaffinised and
hydrated through histoclear and several graded ethanol so-
lutions. The sections were then rinsed in distilled water for
5 mins. To quench the endogenous peroxidase activity, the
tissues were incubated in 0.5 % hydrogen peroxidase in
methanol. The slides were then washed in Tris-buffered
saline (TBS) and incubated with sodium citrate in a pres-
sure cooker for antigen retrieval. Following that, tissues
were washed and incubated with primary antibodies
against IL-33 or ST2 overnight at 4°C. The following
day, the slides were washed in TBS and incubated with
the appropriate biotinylated antibodies for 1 h at room
temperature (RT). The slides were then washed and incu-
bated with horseradish peroxidase (HRP, Sigma-Aldrich)
for 1 h at RT. After the HRP was washed off, the stain-
ing was visualised using Impact DAB solution (Vector
Laboratories), the reaction was stopped with tap water.
The slides were then counter stained using haematoxy-
lin, dehydrated through graded ethanol alcohol solu-
tions and mounted in DPX (Sigma-Aldrich).
Double immunohistochemical staining was performed
by repeating the above procedure however using alkaline
phosphatase in place of HRP and visualising with Vector ®
blue (Vector Laboratories) for the second primary anti-
body specific proteins. For fluorescence staining, FITC or
TRITC-conjugated secondary antibodies were added to
the tissue sections following incubation with the primary
antibodies. Fluorescence staining sections were mounted
with Vectashield containing DAPI (Vector Laboratories).
Isotypes with matching IgG were used as negative controls
for all the immunohistochemical staining.
Myelinationing co-cultures
The protocol of generating myelinating spinal cord cultures
has been previously described in by Sorensen et al. [22] and
reported in some of our recent papers [23, 24]. Briefly neu-
rospheres were derived from the corpus striatum of P1
Sprague Dawley rats and cultured in neurosphere medium
(NSM) supplemented with 20 ng/ml of mouse sub maxil-
lary gland epidermal growth factor (EGF, R & D Systems)
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to promote sphere formation. After 7 days in culture,
neurospheres were carefully collected and transferred to
24 well plates with poly-L-lysine coated coverslips inside
each well (~50,000 cells/coverslip), and cultured in Dul-
becco’s Modified Eagle Medium (DMEM) with 10 %
fetal bovine serum. The cell culture was routinely fed by
removing half of the medium and replacing with fresh
medium. It typically took 7 days before the astrocytes
formed a confluent monolayer on the coverslip. Cover-
slips supporting the astrocytes were then placed in a
small petri-dish before adding dissociated rat embryonic
spinal cord cells.
To obtain the dissociated rat spinal cord cells, E15.5 em-
bryos were obtained from time mated Sprague Dawley fe-
male rats. The cranial 5- to 6- mm sections of spinal cord
from the embryos were dissected and stripped of menin-
ges. Tissues were then dissociated with trypsin and colla-
genase, and plated onto coverslips prepared in the dish
with a density of 150,000 cells/50 μl per coverslip. The
cells were left to attach for 2 h and then 1 ml of differenti-
ation medium, which was DMEM containing 4500mg/ml
glucose, 10ng/ml biotin and 0.5 % N1 hormone mixture
[1mg/ml apotranferrin, 20mM putrescine, 4μM progester-
one, 6μm selenium, 50nM hydrocortisone and 0.5 mg/ml
insulin (Sigma-Aldrich, UK)] was added. The cultures
were fed regularly three times a week by replacing half of
the medium with fresh differentiation medium. After 12
days culture in vitro (DIV), insulin was removed from the
culture medium to promote myelination. The cultures
were maintained for a further period of 14–16 days. From
DIV 18 -28, some myelinating culture cells were fed three
times a week by replacing 500 μl of medium with equal
amount of fresh medium containing recombinant IL-33
(final concentration 25 ng/ml or 100 ng/ml).
Staining and analysis of myelination in the co-cultures
Cells were fixed with 4 % paraformaldehyde for 20 mins,
washed, and followed by permeabilision with 0.5 % Triton
X-100 for 15 mins at RT. Cells were incubated overnight
at 4 °C with specific primary antibodies against ST2,
SMI-31 (neurofilament marker to visualise axons), MBP
(myelin) or Olig2. On the following day, primary antibodies
were removed and coverslips were washed with PBS thor-
oughly before appropriate fluorochrome conjugated sec-
ondary antibodies were added and incubated for a further
15 mins. Coverslips were then washed and mounted to
glass slides in Vectashield (Vector laboratories).
All images taken for analysis of cell number, morphology
and axon/myelin qualification were obtained using an
Olympus BX51 fluoroscent microscope. For myelin ana-
lysis, a minimum of 30 images (x10 magnification) were
taken at random with 10 images per coverslip for each
sample. The images were analysed using the software
Image J. Using this software each image was separated into
three channels i.e. blue, red and green. The axonal density
was determined by calculating the percentage of SMI-31+
pixels compared to the total number of pixels within the
image (also as field). The percentage of myelinated axons
was quantified by placing a transparent layer on top of the
image in Adobe Photoshop® and drawing blue lines over
the MBP+ myelin (green) only focusing on the sheaths.
The myelin was then quantified by using a macro gener-
ated by the group using Image J. Myelination was
expressed as the total number of myelin pixels / total
number of SMI-31 pixels. Data reported here were com-
piled from 3 independent experiments and analysed in the
statistical package JMP8.0 using linear models. Percentage
of axonal density and percentage of myelinated axons
were analysed to determine changes over time and after
the addition of IL-33 at 28 DIV. Significant differences be-
tween groups were determined by Student’s t-test, p <
0.05 was considered to be significant different between
groups.
Results
Altered expression level and pattern of IL-33 in lesions
of MS patient brain tissues
To determine the expression of IL-33 in MS lesions, im-
munohistochemical staining was performed in human
brain tissues from all MS patients and controls as de-
scribed in Materials and Methods. IL-33 specificity was
tested and confirmed using an isotype control antibody
in human lung and brain tissues (Additional file 1: Fig-
ure S1A). Our data show that IL-33 was expressed in
both the cortex and white matter (WM) of healthy con-
trols (Fig. 1a, d). Expression of IL-33 in the cortex and
normal appearing WM (NAWM) from chronic MS pa-
tients was similar to tissues of controls (Fig. 1c, f ). IL-33
reactivity was seen in the cortex in granular form in a
subset of neurons, including their dendrites and in some
glia cells in the cortex and the white matter. However in
cortex, NAWM and lesions of acute MS patients (Fig. 1b,
e, g), IL-33 staining was of higher intensity than the con-
trol and chronic patient tissues. This was particularly
evident in active lesions, where intense reactivity was
present in glia cells and macrophages. In chronic (in-
active) MS lesions, IL-33 reactivity was low and found in
few glia cells and occasionally in axons (Fig. 1h).
Expression of IL-33 by axons, microglia and astrocytes
Co-localisation of IL-33 with CNS resident cells was in-
vestigated next. Double colour staining revealed that IL-
33 expression in the cortex of healthy controls (Fig. 2a
a) and MS patients (Fig. 2a b) was associated with neu-
rons and axons as determined by co-localisation of IL-
33 with the neurofilament marker SMI-31 (Fig. 2a). We
further performed double or triple fluorescence staining
to determine the expression of IL-33 by CNS glia cells,
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and demonstrate that some but not all Iba1 positive
microglia (Fig. 2b, arrows) or GFAP positive astrocytes
(Fig. 2c, arrows) express IL-33. Interestingly, IL-33 is
also co-localised with CA-II, a marker for oligodendro-
cytes (Fig. 2d, arrows), indicating a potential role of IL-
33 in demyelination or remyelination process in MS
disease.
Expression of ST2 in the brain of MS patients and controls
Expression of ST2 in MS patient and control brain tissues
was also examined using immunohistochemistry. ST2 ex-
pression in the cortex of both control and MS brain tissues
was associated with a diffuse pattern of staining (Fig. 3a-f),
suggesting a similar degree of expression of this receptor
on all neurons and glia. It is worth noting that such stain-
ing was not observed when a matching isotype control
antibody was used and specific staining of ST2 was ob-
served in human lung tissues with the same ST2 antibody
(Additional file 1: Figure S1B). A similar diffuse immu-
noreactivity was also seen in the NAWM of chronic MS
patients (Fig. 3f) and WM of control tissues (Fig. 3d).
However, at the edge of active lesions in acute MS (Fig. 3e)
and in the demyelinated center of the lesions (Fig. 3h)
accentuated immunoreactivity on myelinated nerve fi-
bers was seen, possibly reflecting increased ST2 expres-
sion or accessibility on partly damaged myelin. In
addition we found ST2 reactivity in macrophages
within active lesions and in some axonal end bulbs at
sites of axonal transection (Fig. 3g).
Expression of ST2 by axon and oligogendrocytes
To clarify the role of IL-33/ST2 axis in the CNS, it is im-
portant to identify the ST2 positive CNS resident cells. Our
dual staining of ST2 with SMI-31 revealed an expression of
ST2 around axons in MS lesions (Fig. 4a). Further fluores-
cence staining experiment revealed that ST2 was expressed
by some oligodendrocytes as determined by co-localisation
of ST2 with CA-II (Fig. 4b). Thus our data here suggest a
potential role for IL-33/ST2 signalling in the demyelination
and/or remyelination process in CNS degenerative diseases
such as MS.
A role for IL-33/ ST2 signalling in myelination
Expression of ST2 around damaged axons and by oligo-
dendrocytes in CNS lesions of MS patients (Fig. 4) led to
our investigation of whether myelination is affected by IL-
33/ ST2 signalling. A well established rat CNS myelinating
co-cultures was generated as described previously [22–24]
and cells were treated with recombinant IL-33, after 16
days the number of oligodendrocytes, density of axons
and myelinated axons was assessed. Our results show that
the number of oligodendrocytes in the culture, indicated
by Olig2 staining, increased significantly after 12 DIV in
accordance with the removal of insulin from the culture
media which inhibited myelination prior to this point
(Additional file 2: Figure S2). Similar increase was also
observed with MBP positive staining (Additional file 3:
Figure S3) while the increase of SMI-31 expression (i.e.
axons) was not significant.
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Fig. 1 Expression of IL-33 (brown) in healthy and MS brain patient samples. Immunohistochemical staining was used to determine the expression
of IL-33 in the cortex and WM of healthy brain samples, and in the cortex, NAWM and lesion of acute and chronic MS patients. a cortex and d white
matter of healthy brain tissues; b cortex, e NAWM and g lesion of acute MS brain sample; c cortex, f NAWM and h lesion of chronic MS brain sample
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To determine whether IL-33 receptor ST2 was expressed
by the cultured CNS cells, we carried out a series of immu-
nohistochemical staining and our results confirmed that
ST2 is expressed by some neurons (Fig. 5a) and oligoden-
drocytes (Fig. 5b) but not astrocytes (Fig. 5c), which agrees
with our in situ staining of ST2 by oligodendrocytes in hu-
man brain tissues. To test the effect of IL-33 on myelin-
ation, 25ng/ml or 100 ng/ml recombinant IL-33 was added
to the culture at 12 DIV and similar effect was observed
between the two groups. Our results show that there was
no significant difference between the axonal densities of
control and IL-33 treated cultures at 28 DIV as shown by
the percentage of SMI-31+ axons (Fig. 6a and b), indicating
that IL-33 does not impact the growth or viability of neu-
rons and axonal formation. Surprisingly treatment with IL-
33 resulted in a significant reduction in the proportion of
myelinated axons (Fig. 6a and c) in the myelinating co-
cultures, suggesting that IL-33 may have an inhibitory ef-
fect on myelination.
Discussion
Despite recent research interest in the role of IL-33 in
CNS diseases, the precise cellular source and expression
levels of IL-33 and ST2 in-situ in human have not been
a
b
c
d
Fig. 2 Expression of IL-33 by CNS resident cells in human. a Co-staining of IL-33 (brown) with SMI-31 (blue), a marker for neuron and axons, in cortex
of normal human brain (a) and MS acute lesion (b). b Co-staining of IL-33 with Iba1, a marker for microglia cells, in human brain samples. Arrows
indicate colocalization of IL-33 with Iba-1. c Co-staining of IL-33 with GFAP, a marker for astrocytes (arrows) in human brain samples.
d Co-staining of IL-33 with CA-II, a marker for oligodendrocytes (arrows) in human brain samples
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conclusively determined. Our study here demonstrates
that IL-33 protein is expressed by various CNS resident
cells including neurons, astrocytes, oligodendrocytes
and microglia cells, while its receptor ST2 is predomin-
antly expressed by neurons and oligodendrocytes. In
addition, the expression levels and patterns of IL-33 and
ST2 in the lesions of acute and chronic MS patient brain
samples were enhanced compared with the healthy
brain tissues. Our study using rat myelinating co-
cultures further revealed that IL-33 inhibits CNS mye-
lination, thus suggesting how it may contribute to MS
pathology.
a b c
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Fig. 3 Expression of ST2 (brown) in healthy and MS patient brain samples. Immunohistochemical staining was used to determine the expression of
ST2 in the cortex and WM of healthy brain samples, and in the cortex, NAWM and lesion of acute and chronic MS patients. a cortex and d white
matter of healthy brain tissues; b cortex, e NAWM and g lesion of acute MS brain sample; c cortex, f NAWM and h lesion of chronic MS brain sample
a
b
Fig. 4 Expression of ST2 by CNS cells in human. a Co-staining of ST2 (green) with SMI-31 (red), a marker for axons, in human brain samples. Arrows
indicate expression of ST2 around SMI-31 expressing axons. b Co-staining of ST2 (green) with CA-II (red) positive oligodendrocytes in human brain
samples. Arrows indicate colocalization of ST2 with CA-II expressing oligodendrocytes
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Numerous studies have attempted to identify the expres-
sion of IL-33 and ST2 in CNS cells, however the results
are confusing as some studies used in vitro cultured CNS
cells, and others mainly focused on glial cells such as as-
trocytes [25–27]. Nevertheless findings from these studies
have indicated that astrocytes are an important potential
source of IL-33 in both mouse and human [16, 18, 25, 26],
and that IL-33 released by astrocytes activates microglia
cells during CNS diseases [25]. Our study here using in situ
immunohistochemical staining confirms the co-localisation
Fig. 5 Expression of ST2 by CNS cells in rat melinating co-cultures. Double immunofluorescence staining of ST2 (green) and antibodies against
NeuN (red, marker for neuron cells) and GFAP (red, astrocyte marker), and the O4 antibody (red, a marker for immature oligodendrocytes and
mature progenitor cells) in the cultured CNS cells at 12 DIV
a
b c
Fig. 6 Recombinant IL-33 inhibits axon myelination in rat myelinating co-cultures. The cell cultures were treated with or without recombinant
IL-33 from DIV 12 to 28, a and the cells immuno-labelled with SMI-31 and anti-MBP, markers for axons and mature myelin respectively. b Graph depicting
the percentage of SMI-31+ cells in total field of view. c Graph depicting the percentage of myelination measured by MBP+ and SMI-31+ overlapping
pixels/total SMI31 pixels. * P < 0.05. Data are presented as Mean + SEM, and were compiled from three independent experiments
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of IL-33 with GFAP in human brain tissues. Furthermore,
we have revealed that astrocytes are not the exclusive
source of IL-33 as our data demonstrate that IL-33 is also
expressed by neurons. The expression of IL-33 by microglia
cells remains controversial [26, 28]. Our data clearly indi-
cate a co-localisation of IL-33 with some Iba1 expressing
cells, suggesting a potential source of IL-33 by microglia
cells, as proposed by Xiong et al. in AD [29].
While most research focus has been on IL-33, the ex-
pression of ST2 by CNS cells is less clear. ST2 mRNA was
detected in cultured murine microglia and astrocyte cells
[26]. As IL-33 is well known to induce the polarisation of
alternatively activated (M2-like) macrophages in diseases
such as asthma [30] and obesity [31], and M2-like micro-
glia cells contribute to neuroprotection [32], expression of
ST2 by microglia cells therefore may suggest that IL-33
plays an important role in MS development through
modulating the polarisation of microglia cells in the CNS.
Our in situ staining data here show that ST2 is accentu-
ated around SMI-31 labelled axons and CA-II labelled oli-
godendendrocytes in human brains. The data with cross
expression of IL-33 and ST2 by various CNS cells suggest
complex autocrine and paracrine mechanisms of IL-33/
ST2 signalling in the CNS compartment.
It has been well documented that IL-33 is a pleiotropic
cytokine [10, 33–35] in regulating immune responses in
various immune mediated diseases [36–38], and systemic
administration of recombinant IL-33 to EAE mice after
disease onset induces type 2 immune responses and re-
duces CNS inflammation [18]. The apparent up-regulation
of IL-33 and ST2 at the acute lesions of MS patients indi-
cates that IL-33 signalling is enhanced in CNS inflamma-
tion, thus suggesting a role for IL-33 in the pathogenesis
of MS disease. Furthermore, the expression of both IL-33
and ST2 by various CNS cells indicates that IL-33/ST2 is
likely to have its unique CNS specific function in addition
to its immunomodulatory roles during CNS inflammation.
However, its precise function in the CNS under normal
and disease conditions remains poorly understood. Most
current studies suggest that glial cell-released IL-33 acti-
vates neighbouring cells to produce inflammatory mole-
cules, which further impact on the neuronal function in
CNS, being either protective [5] or pathogenic [26, 29]
under different disease conditions. The implication of
Il-33 gene polymorphism in the etiology of AD disease
[13, 14] had led to a further investigation [29], which
reported that IL-33 and ST2 positive cells were signifi-
cantly increased in the AD brains when compared with
non-AD brains, and the expression was associated with
signatures of AD pathology (e.g. amyloid plagues and
neurofibrillary tangles). The authors proposed that IL-33/
ST2 axis may play an important role in AD pathogenesis
via inducing inflammatory molecules released from the
glial cells. In our study, while only a small increase of IL-
33 expression was observed in the NAWM of MS pa-
tients, its levels were dramatically enhanced in active
lesions of MS, which is in good agreement with previ-
ous findings of increased IL-33 mRNA at the lesion of
MS patients by Christophi et al. [16]. While less is
known about the expression of ST2 in the CNS, our
data clearly show that the diffuse expression of ST2 in
normal human cortex changed to an accentuated stain-
ing in the MS lesions in axons and in potentially dam-
aged myelin, confirming a role for IL-33/ST2 pathway
in MS disease.
Whether IL-33 has detrimental or beneficial effect on
MS development and what are the underlying mecha-
nisms are yet to be determined. Kempuraj et al [39] sug-
gested the involvement of IL-33 in neurodegeneration and
neuronal death as incubation of mixed astrocytes and neu-
rons or neuronal culture with IL-33 reduced the number
of microtubule-associated protein-2-immunoreactive cells.
While several other studies confirmed the expression of
IL-33 by murine oligodendrocytes [5, 11, 40], our observa-
tion of IL-33 and ST2 expression by oligodendrocytes in
human CNS tissues support a role for IL-33/ST2 in CNS
demyelination or remyelination. In order to understand
the effect of IL-33 on CNS myelination, we used well-
established rat CNS myelinating co-cultures. While IL-33
was shown to have no effect on the density of axons, our
study show for the first time that IL-33 was able to inhibit
axon myelination significantly. Whether IL-33 contributes
to the initial demyelinating step, or is also involved in the
following neurodegeneration in vivo remains unclear and
merits further in-depth investigation. It is worth noted
that the data were obtained using a rat myelinating cul-
ture system, our preliminary data from a mouse myeli-
nating culture system showed no statistical significance
of axon myelination with the presence of IL-33 in the
culture (data not shown). It will need further investiga-
tion to understand whether this is a real species-
specific difference or culture condition difference as the
rat CNS culture system requires a pre-prepared single
layer of astrocytes, which is not needed in the mouse
culture.
Although the myelinating cultures do not mimic the
complex in vivo model of demyelinating diseases, our
data indicate the importance of IL-33/ST2 axis in MS
development, possibly via its involvement in myelination
process in CNS, in contrast to the protective anti-
inflammatory function of recombinant IL-33 [18] and
spinal cord-released IL-33 [28] in EAE. These findings
however indicate the complex interplay between the CNS
and immune system, and the different roles many cyto-
kines play, e.g. TNF-α not only regulates inflammation
but also performs a distinct set of other functions within
the CNS compartment [41]. It is therefore important to
fully define the roles of IL-33 in both systems before
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considering it as a new therapeutic target or reagent for
MS disease.
Conclusions
Together, the present study demonstrates that IL-33
and ST2 are highly expressed by various CNS resident
cells, and there was a change of the expression levels
and patterns of both molecules in the CNS lesions of
MS patients compared with healthy brain tissues. Fur-
thermore, IL-33/ST2 signalling pathway may have its
unique important function in the myelination process
in the CNS compartment, thus contributing to MS
disease development.
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Additional file 1: Figure S1. Immunohistochemical staining of IL-33
and ST2 in human lung tissues. (A) IL-33 matched isotype control antibody
staining in human lung (a) and brain (b) samples, and IL-33 staining in
human lung sample (c and d). (B) ST2 matched isotype control antibody
staining in human lung (a) and brain (b) tissues; ST2 staining in human lung
sample (c and d). (a, b and c), x10 magnification; d. x25 magnification.
(PDF 215 kb)
Additional file 2: Figure S2. The number of oligodendrocytes in the
rat CNS myelinating co-cultures. (A) Percentage of Olig2+ cells in total
field. (B) Images of Olig2 staining in the culture system at DIV 12, 18 and
28. Data are presented as Mean + SEM, and were compiled from three
independent experiments. (PDF 189 kb)
Additional file 3: Figure S3. The number of axons and myelinated
axons at DIV 12, 18 and 28 of the rat CNS myelinating culture. (A) Percentage
of SMI-31+ cells in view field; (B) Percentage of MBP+ axons in view filed.
(C) Representative images of SMI-31 and MBP staining in the myelinating
culture at DIV 12, 18 and 28. Data are presented as Mean + SEM, and were
compiled from three independent experiments. (DOC 356 kb)
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